Group 1 - The core viewpoint of the article highlights that Baoyi Pharmaceutical-B (02659) has seen a significant stock price increase of over 6%, reaching a new high of 190 HKD, following its inclusion in the Hang Seng Composite Index as announced by the Hang Seng Index Company on February 13 [1] - The inclusion in the index is set to take effect after the market closes on March 6, 2026, and will expand the investment scope for the Hong Kong Stock Connect, potentially providing new growth opportunities for Baoyi Pharmaceutical [1] - Baoyi Pharmaceutical is recognized for its innovative products, including KJ017, the first recombinant hyaluronidase in China for large-volume subcutaneous administration, and KJ103, a globally first IgG degrading enzyme with best-in-class potential for antibody-mediated autoimmune diseases [1] Group 2 - The company has established a clear commercialization model and timeline for its upcoming and current products, with KJ017 expected to receive NDA approval in the first quarter of 2026 [1] - The long-acting follicle-stimulating hormone drug SJ02 has also been validated through collaboration, indicating the company's commitment to advancing its product pipeline in assisted reproduction [1]
宝济药业-B逆市涨超6%破顶 获纳入恒生综合指数 KJ017预计于26年首季度获NDA批准